Altimmune vs Eli Lilly vs Novo Nordisk and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Altimmune 0, Eli Lilly 22.974, Novo Nordisk 12.087, Pfizer 15.034.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Altimmune, Eli Lilly, Novo Nordisk, Pfizer.| Metric | Altimmune | Eli Lilly | Novo Nordisk | Pfizer |
|---|---|---|---|---|
| Market Cap | $604.95M | $1.12T | $206.69B | $159.99B |
| Revenue | $0 | $22.97B | $12.09B | $15.03B |
| Cost of Revenue | $0 | $3.27B | $2.63B | $4.09B |
| Gross Profit | $0 | $19.71B | $9.45B | $10.94B |
| Operating Income | $-26.00M | $8.98B | $4.17B | $4.71B |
| Net Income | $-23.00M | $7.09B | $3.23B | $-246.00M |
| R&D Expense | $19.00M | $3.82B | $2.74B | $2.81B |
| Earnings Per Share | -$0.12 | $7.94 | $0.73 | -$0.04 |
| Gross Margin | 100.0% | 85.8% | 78.2% | 72.8% |
| Operating Margin | -111126.9% | 39.1% | 34.5% | 31.3% |
| Net Profit Margin | -105223.1% | 30.9% | 26.7% | -1.6% |
| Free Cash Flow | $-24.00M | $7.76B | $6.53B | $302.00M |
| Cumulative Free Cash Flow | $-249.67B | $109.66B | $107.39B | $356.70B |
| Operating Cash Flow | $-24.00M | $10.69B | $8.50B | $835.00M |
| Cash & Equivalents | $63.00M | $8.89B | $6.85B | $976.00M |